Krystal Biotech, Inc.KRYSNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-8.50%
↓ 155% below average
Average (36q)
15.55%
Historical baseline
Range
High:203.81%
Low:-20.65%
Volatility
1443.4%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -8.50% |
| Q2 2025 | 1.09% |
| Q1 2025 | 5.41% |
| Q4 2024 | 0.09% |
| Q3 2024 | -13.30% |
| Q2 2024 | 42.22% |
| Q1 2024 | -3.63% |
| Q4 2023 | 6.97% |
| Q3 2023 | -12.48% |
| Q2 2023 | -1.17% |
| Q1 2023 | 14.40% |
| Q4 2022 | -6.73% |
| Q3 2022 | 5.75% |
| Q2 2022 | 23.02% |
| Q1 2022 | -1.74% |
| Q4 2021 | 48.17% |
| Q3 2021 | -7.79% |
| Q2 2021 | 6.34% |
| Q1 2021 | 9.33% |
| Q4 2020 | 11.22% |
| Q3 2020 | 40.15% |
| Q2 2020 | 3.23% |
| Q1 2020 | -18.95% |
| Q4 2019 | 11.94% |
| Q3 2019 | -7.85% |
| Q2 2019 | 33.12% |
| Q1 2019 | 13.03% |
| Q4 2018 | 46.39% |
| Q3 2018 | 25.51% |
| Q2 2018 | 0.33% |
| Q1 2018 | 39.71% |
| Q4 2017 | -19.70% |
| Q3 2017 | 203.81% |
| Q2 2017 | 39.81% |
| Q1 2017 | -20.65% |
| Q4 2016 | 66.80% |
| Q3 2016 | 0.00% |